MENU
Aim higher

Foxy-5

Development of Foxy-5 as a first in class anti-metastatic cancer drug

Foxy-5 is a small peptide that mimics the effects of the protein Wnt-5a. Foxy-5 inhibits the development of metastasis and thereby increase survival rates in patients with breast and in particular colorectal cancer. Tumour metastasis is the predominant cause of death among cancer patients.
Acronym: 
Foxy-5
Project ID: 
7 090
Ranking: 
19
Cut-off: 
7
Start date: 
01-03-2012
Project Duration: 
48months
Project costs: 
6 098 360.00€
Technological Area: 
Medical technology
Market Area: 
Therapeutic